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Abstract
Background: Human mesial temporal lobe epilepsies (MTLE) represent the most frequent form of partial epilepsies and are
frequently preceded by febrile seizures (FS) in infancy and early childhood. Genetic associations of several complement
genes including its central component C3 with disorders of the central nervous system, and the existence of C3
dysregulation in the epilepsies and in the MTLE particularly, make it the C3 gene a good candidate for human MTLE.
Methodology/Principal Findings: A case-control association study of the C3 gene was performed in a first series of 122
patients with MTLE and 196 controls. Four haplotypes (HAP1 to 4) comprising GF100472, a newly discovered dinucleotide
repeatpolymorphism[(CA)8to(CA)15] intheC3promoterregionshowed significantassociationafter Bonferronicorrection,in
the subgroup of MTLE patients having a personal history of FS (MTLE-FS+). Replication analysis in independent patients and
controls confirmed that the rare HAP4 haplotype comprising the minimal length allele of GF100472 [(CA)8], protected against
MTLE-FS+. A fifth haplotype (HAP5) with medium-size (CA)11 allele of GF100472 displayed four times higher frequency in
controlsthaninthefirst cohort of MTLE-FS+ and showed a protective effect againstFSthrough a high statistical significance in
an independentpopulationof 97 pure FS.Consistently, (CA)11 allele byitsownprotectedagainstpureFS ina secondgroupof
148 FS patients. Reporter gene assays showed that GF100472 significantly influenced C3 promoter activity (the higher the
number of repeats, the lower the transcriptional activity). Taken together, the consistent genetic data and the functional
analysis presented here indicate that a newly-identified and functional polymorphism in the promoter of the complement C3
gene might participate in the genetic susceptibility to human MTLE with a history of FS, and to pure FS.
Conclusions/Significance: The present study provides important data suggesting for the first time the involvement of the
complement system in the genetic susceptibility to epileptic seizures and to epilepsy.
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Introduction
The mammalian complement system is a key component of
innate immunity and participates in adaptive immunity. It is
composed of more than 30 plasma and cell surface proteins that
interact in a very precise and regulated way[1]. Besides their
canonical roles, there is increasing evidence that components of
the complement system also participate in various physiological
processes of the central nervous system (CNS) such as synapse
elimination during development[2] or adult neurogenesis[3].
Complement activation may occur in several CNS pathological
conditions[4,5], including Alzheimer’s disease[6] and multiple
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12740sclerosis[7]. Several proteins with complement control modules
such as LEV-9[8] and SRPX2[9] are involved in acetylcholine
receptor clustering at the synapse in Caenorhabditis elegans or in
developmental disorders of the speech cortex, respectively.
Polymorphisms in genes encoding several complement factors
have been successfully associated with age-related macular
degeneration[10]. More recently, genome-wide association studies
showed involvement of the complement lysis inhibitor (Clusterin)
gene and of the complement component receptor 1 (CR1) gene in
the genetic risk to late onset Alzheimer’s disease[11,12].
Experimental evidences for a role of the complement system in
epileptic processes have also been reported[13,14]. Increased
expression of C3 gene and protein, and activation of the
complement system have been found in brain tissues from patients
with mesial temporal lobe epilepsy (MTLE)[15,16] and from
rodent MTLE model[17]. Human MTLE are the most frequent
form of partial epilepsies and frequently display resistance to anti-
epileptic drugs[18]. Hence MTLE represent a major health care
problem. The MTLE phenotype is frequently associated with
history of often-complex febrile seizures (FS) and/or with
hippocampal sclerosis (HS). Familial cases with a Mendelian
mode of inheritance have been reported[19,20,21] and a few
MTLE loci have been mapped[22,23,24] but no gene has been
identified yet. Moreover, most MTLE cases look sporadic and may
be influenced by variations in multiple genes as well as by
environmental factors. It is believed that the identification of
susceptibility genes for MTLE will be obtained by a combination
of genetic mapping and candidate gene strategies[25]. Indeed,
numerous association studies have suggested the involvement of
various genes in human MTLE[22] but data have mainly shown
negative or conflicting[26,27].
There is growing evidence for an important role of the
complement system in CNS development and functioning and
for the involvement of the complement system and particularly of
C3 dysregulation, in the epilepsies – including the MTLE. Hence,
the C3 gene represented a good candidate for the genetic
susceptibility to human MTLE. In the present study, we identified
a novel functional, regulatory CA-repeat polymorphism
(GF100472) within the promoter region of C3 and aimed at
evaluating the possibility of genetic association between human
MTLE and GF100472-related haplotypes.
Results
Novel microsatellite repeat (GF100472) within the C3
promoter region
The C3 component is encoded by the C3 gene (Genbank
NM_000064) located at chromosome 19p13. This gene extends
over 42.8 kb and encompasses 41 exons (http://genome.ucsc.
edu/). As a primary analysis we focused on the C3 promoter
region and on its genetic variations that may sustain modulation of
C3 transcriptional activity. The promoter region of C3 spans more
than 1 kb[28,29]. Several C3 regulatory elements have already
been described, 59 to the canonical transcription start site (+1) that
in turn is situated 61 nucleotides (nt) upstream from the start
codon (Figure 1). These include IR-1 element[30], IL6/ILb1
responsive element[31], estrogen-response elements[32], binding
sites bZIP1 and bZIP2 for transcription factor C/EBPD[29,33] as
well as putative CAAT and TATA boxes[29]. Careful examina-
tion of more distal 59 sequences revealed the existence of a CA
dinucleotide repeated eight times – (CA)8 – according to the
reference human genome sequence at UCSC website (http://
genome.ucsc.edu/) (Figure 1). Although this repeat sequence was
reminiscent to classical (CA)n dinucleotide polymorphisms, it did
not correspond to any previously annotated polymorphic micro-
satellite marker. Genotyping analysis of 196 Caucasian controls
(series HI-1) revealed length polymorphisms in this (CA)n repeat,
with n ranging from n=8 to n=15. Most frequent alleles were
(CA)8 (39%), (CA)11 (30%), (CA)12 (19%), and (CA)15 (11%).
Two other alleles (n=9; n=10) showed much lower frequencies
(,1%) (Table S1). Those results were confirmed in an indepen-
dent population of 255 healthy individuals (series HI-2) as well as
in a third series (HI-3) of 301 additional Caucasian controls (Table
S1). In addition, 54 Caucasian control trios were genotyped to
assess the inheritance of this (CA)n repeat. This novel micro-
satellite repeat was given accession number GF100472 (database
of sequence tagged sites at NCBI: http://www.ncbi.nlm.nih.gov/
dbSTS/).
Multi-markers analysis identified putative at-risk and
protective haplotypes for MTLE patients with history
of FS
To test for genetic association between human MTLE and the
GF100472 microsatellite marker located within the C3 promoter
region, a first series (MT-1) of 122 MTLE patients was collected
(Table 1). Amongst the 122 patients, 57 (MTLE-FS+ patients) had
a history of febrile seizures (FS) and 87 (MTLE-HS+ patients)
showed hippocampal sclerosis (HS) on magnetic resonance
imaging (MRI). Of note, 87.7% of the MTLE-FS+ patients also
displayed HS. All patients (68 females, 54 males) as well as 196
matched controls (series HI-1) that were included in this first case-
control study were European Caucasian for at least two
generations. In addition to GF100472, five single nucleotide
polymorphisms (SNPs) were analyzed (Figure 1). These were
selected according to their respective minor allele frequencies and
to their locations, owning to distinct haplotype blocks spanning C3
(International HapMap project website at: http://www.hapmap.
org/). For each SNP, allele and genotype frequencies in control
series HI-1 were consistent with those reported from the reference
population of European descent (Population HapMap CEU at
http://www.ncbi.nlm.nih.gov/SNP/) (Table S1). Single marker
association analysis detected a significant difference in the
distribution of CA-repeat alleles between controls and MTLE-
FS+ (p=0.036) and between controls and MTLE-HS+ (p=0.042)
(Table S2). This difference was mainly accounted by a higher
frequency of allele (CA)15 in patients than in controls (Table S1).
However, this association did not resist Bonferroni correction for
multiple testing.
The six polymorphic markers, i.e. rs339392, GF100472,
rs2230199, rs428453, rs344550, and rs379527, from the 59 to the
39 end of the C3 gene (Figure 1), were then included for haplotype
analysis. Two six-markers haplotypes that differed for markers
GF100472, rs428453, rs344550, and rs379527, T-(CA)15-C-G-C-
T and T-(CA)11-C-C-G-G, showed higher (p=0.037, p=0.0064
and p=0.00041) and lower (p=0.013, p=0.0057 and p=0.013)
frequencies, respectively, in MTLE, MTLE-HS+ and MTLE-FS+
patients.Tostrengthen thepowerofouranalysisand tohighlightat-
risk and protective haplotypes, the analysis was then done with
haplotypes formed by three-markers combinations and excluding
rs339392 and rs2230199.
Four three-markers haplotypes showed significant associations
after correction for multiple testing (Table S3). Interestingly, two
haplotypes (HAP1 and HAP2) containing the GF100472 (CA)15
allele were associated with MTLE-FS+ (p=0.005 and p=0.007,
respectively). Conversely, haplotype HAP3 that included the
(CA)8 allele was protective against MTLE-FS+ (p=0.003). Finally,
a rare haplotype (HAP4) also comprising the (CA)8 allele was also
protective (p=0.0003). As multiple positive findings were expected
Complement C3 Gene in Epilepsy
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quantify the joint probability of multiple findings reflecting true
associations as opposed to false positives, taking into account all
comparisons performed to test the three hypotheses. The six top
associations of the multiple comparisons (Table S3) were
attributed a q value of 0.21 or less. While, after multiple
comparison correction, it was not possible to reject all of the null
hypotheses at a conventional level of statistical significance, all six
Table 1. Demographic and clinical characteristics of two series (MT-1, MT-2) of MTLE patients, of two series (FS-1, FS-2) of FS
patients and of three series (HI-1 to 3) of control individuals.
Variables HI-1 (N=196) HI-2 (N=255) HI-3 (N=301) MT-1 (N=122) MT-2 (N=199) FS-1 (N=97) FS-2 (N=148)
Male (%) 109 (55.6) 144 (56.5) 171 (56.8) 54 (44.3) 81 (40.7) 54 (55.7) 81 (54.7)
Female (%) 87 (44.4) 111 (43,5) 130 (43.2) 68 (55.7) 118 (59.3) 43 (44.3) 67 (45.3)
AO, yr, mean 6 SD – – – 15.5865.21 NA 3.4361.61 NA
HS (%) – – – 87 (71.9) 119 (59.8) – –
Personal hist.
of FS (%)
0 (0) 0 (0) 0 (0) 57 (50.8) 46 (23.1) 97 (100) 148 (100)
Simple FS (%) – – – 38 (66.4) NA 83 (85.6) 67* (66.3)*
Complex FS (%) – – – 19 (33.6) NA 14 (14.4) 34* (33.7)*
Family hist.
FS/epilepsy (%)
0 (0) NA 0 (0) 29 (23.8) 49 (24.6) 19 (19.6) NA
MTLE: Mesial temporal lobe epilepsy. HS: hippocampal sclerosis. FS: Febrile seizures. AO: age at onset. SD: standard deviation. yr: years. hist: history. NA: not available.
*: FS status (whether simple or complex) unknown in 47 patients.
doi:10.1371/journal.pone.0012740.t001
Figure 1. Promoter region of the human complement C3 gene. Schematic diagram of (top) the human complement C3 gene with exon/intron
genomic structure, and (bottom) of its promoter region from the CA-repeat polymorphism marker GF100472 to the start codon. Regulatory elements
and nucleotide (nt) positions respective to the canonical transcription start site (+1) are indicated.
doi:10.1371/journal.pone.0012740.g001
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that all the six findings are false positives is 0.00009).
Replication analysis in MTLE-FS+ patients
The highly conservative Bonferroni correction[34] as well as the
results of the false discovery rate analysis indicated that at least a
subset of the significant data depicted above were likely true
positives. However, it remained necessary to confirm and refine
our data by performing a replication study in independent case
and control samples. A novel set of experiments was thus
conducted in new series of 199 MTLE patients (MT-2 series)
and 255 control individuals (HI-2 series). While HAP1, 2 and 3 did
not show any significant difference between the novel MTLE-FS+
cases and the novel controls (data not shown), data of the
protective and rare HAP4 haplotype were replicated in the novel
subset of MTLE-FS+ patients with high statistical significance
(p=0.00008) (Table S3).
Analysis in pure FS populations
MTLE-FS+ and pure FS patients may well share some
susceptibility genes in common[22]. Hence, an independent
population of 97 patients having pure FS (series FS-1) was studied.
The (CA)11 allele showed an increased frequency in HI-1 controls
(30%) as compared to FS patients (24%) (Table S1). Although this
difference did not reach statistical significance, this tendency
suggested a possible involvement of (CA)11 in the genetic risk for
pure FS. Indeed, one (CA)11-containing haplotype (HAP5) was
found to be protective with high statistical significance
(p=2.222610
28) when comparing controls frequency (8.9%) to
FS patients frequency (0%) (Table S3). Interestingly, HAP5 had
also been found four times less frequent in MTLE-FS+ patients
from series MT-1 than in HI-1 controls (Table S3). In order to
assess this result, a replication study was performed in an
independent set of 148 pure FS patients (FS-2 series) and in the
HI-2 series of control individuals. Compared to the former FS
study, a consistent albeit mirror situation was obtained. As in the
first FS-1 series, HAP5 was not found in any FS patient, but data
did not reach the significance threshold (Table S3). However, the
sole (CA)11 marker contained within HAP5 was significantly
(p=0.007) more frequent in controls (27%, series HI-2) than in FS
patients (18%, series FS-2) (Table S1). Moreover, when both FS-1
and FS-2 populations on the one hand, and both HI-1 and HI-2
control samples on the other hand, were merged as a single FS
group and a single control group, respectively, data for (CA)11
remained significant (p=0.001). No statistical difference was
observed when the distribution of haplotypes was compared
between patients with MLTE-FS+ and those with pure FS.
Modulation of C3 promoter activity by GF100472
microsatellite length polymorphism
Altogether, our data indicated that the GF100472 microsatellite
marker in the C3 promoter region, influences the risk for MTLE-
FS+ and for FS, by acting either on its own or at least partly in
combination with other C3 polymorphisms. Generally promoter
polymorphisms might influence expression level of a gene that
could account for susceptibility to develop a particular disorder.
The influence on gene expression of various CA-repeats located
within intronic[35] or within promoter[36,37,38] regions has long
been described. To test for a possible effect of GF100472 on C3
gene expression, an in vitro luciferase reporter gene assay was
performed, by subcloning into the promoterless plasmid pGL2,
several variants of the C3 promoter regions – from nucleotides
21021 to +61 with respect to the canonical C3 transcription start
site (Figure 1). The promoter regions contained either of
GF100472 alleles (CA)8, (CA)9, (CA)10, (CA)11 and (CA)15,
and only differed in this number of CA-repeats, as further verified
by direct full-length sequencing of each insert. Despite repeated
attempts, no clone corresponding to allele (CA)12 could be
obtained. Promoter constructs were transiently transfected into
human embryonic kidney 293 (HEK293T) cells in order to
compare their ability to drive luciferase gene expression. In a first
assay, the two extreme sizes alleles [CA)8 and (CA)15] were
compared. Relative levels of luciferase expression were measured
in three independent experiments and indicated that the longest
allele (CA)15 of GF100472 had significantly reduced promoter
activity (80.69% of activity; p,0.001, unpaired t-test) as compared
to the shortest allele (CA)8 (Figure 2A). All five alleles were then
tested in a novel set of three independent experiments, which
confirmed and extended the above data and showed that the the
longer the GF100472 allele, the lower the C3 promoter activity
(Figure 2B).
Discussion
Genetic contribution to human MTLE is well recognized but
little is known about the genes participating in the underlying
pathophysiology[25]. While there had been previous arguments
for dysregulation of the complement system in various epileptic
models and in the human MTLE particularly[15], the genetic
influence of the complement system on the risk for epilepsy and
seizures had not been suggested so far. In the present study,
replicated genetic data and functional analysis suggest that a
newly-identified and functional dinucleotide polymorphism
(GF100472) in the complement component C3 promoter influ-
ences genetic susceptibility to human MTLE with a history of FS
(MTLE-FS+), and to pure FS. One rare C3 haplotype (HAP4) that
encompasses the GF100472 shortest length allele [(CA)8],
protected against MTLE-FS+ in two independent populations of
patients vs controls. Another rare C3 haplotype (HAP5) was also
found protective in an independent population of pure FS and was
also much less frequent in MTLE-FS+ patients than in controls.
Moreover, the GF100472 allele (CA)11 contained within HAP5,
was also protective by itself in a replication study composed by
novel series of FS patients and controls. Noteworthingly, HAP4
did not show any significant difference in an independent
population of pure FS compared to matched controls. Several
reasons may account for this latter data. The first one is a
difference of power between the studies, hence masking some of
the statistical effects. Different genetic contributions to FS
developed earlier in life by patients with MTLE, and to FS
displayed by the general population, might represent another and
non exclusive possibility. MTLE-FS+ patients are very often
considered as having complex FS[39] while FS in the general
population would represent a more balanced mix of simple and
complex FS. Indeed, in the present study 19 out of the 57 MTLE-
FS+ patients (series MT-1) had complex FS as compared to 14 out
of 97 FS patients (series FS-1) (33.6% versus 14.4%; p=0.006). On
the one hand, HAP4 could be specific to complex FS of MTLE
patients and hence its effect would be diluted in the FS general
population. For instance, HAP4 could influence a sequence of
events leading from FS to MTLE[40] rather than directly
influencing the risk of FS. On the other hand, HAP5 – including
(CA)11 – might protect against FS and against MTLE as a shared
susceptibility factor.
If taken separately, each association found in this study is to be
considered with caution and moderate significance, both because
of the limited number of patients in each MTLE and FS
Complement C3 Gene in Epilepsy
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haplotypes. In such cases, there always is an inherent risk of false
positive result due to chance or to bias such as occult
stratification. Although this risk cannot be excluded for each
separate association, the following points are noteworthy as, all
taken together, they strongly argue in favor of the actual
participation of the C3 gene in the genetic susceptibility to
MTLE-FS+ and to FS. First of all, the very conservative
Figure 2. Luciferase reporter assays. (A) Comparison of the two alleles of marker GF100472 with the extreme sizes [(CA)8 and (CA)15] and (B) with
either of GF100472 alleles (CA)8, (CA)9, (CA)10, (CA)11 and (CA)15. pGL2 vector containing the C3 promoter region with different CA-repeat variants
[(CA)8, (CA)9, (CA)10, (CA)11 and (CA)15] was cotransfected into HEK293T cells with a b-galactosidase expression vector (pHSV-LacZ) for normalization
of transfection efficiencies. In parallel, empty (promoterless) vector (pGL2-basic) was transfected with pHSV-LacZ. Transcriptional activities were
determined by quantifying the luciferase activity of cellular extracts prepared 48 h after transfection. Relative luciferase activity of (CA)8 was defined
as 100. Data show the mean 6 SD relative activity from three experiments done in triplicate. Statistical significances were determined by two-tailed
unpaired t test. (**) indicates p,0.001. (*) indicates p,0.05. (NS) indicates non significant.
doi:10.1371/journal.pone.0012740.g002
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effects of multiple testing. Moreover, the false discovery rate
analysis also pointed at the existence of true positives. Secondly,
protective effect of HAP4 against MTLE-FS+, while significantly
displayed in samples of small sizes, was replicated in independent
patients and controls groups. That rare alleles can indeed
influence susceptibility to common disorders is increasingly
recognized; as an example, the 15q13 microdeletion variant that
was present in 1% of patients with idiopathic generalized
epilepsy and that was virtually absent from controls (,0.02%), is
associated with strong epileptogenic effect [41]. Thirdly, the
protective effect of (CA)11-containing HAP5 haplotype in a first
series of FS patients, was consistent with the protective effect of
(CA)11 allele alone in a novel and independent FS population.
Moreover, C3 maps right within the 19p critical area where
linkage of autosomal dominant FS trait (FEB2 locus) has been
reported[42]. Fourthly, there is an obvious clinical overlap
between MTLE-FS+ and FS patients and the C3 susceptibility
gene was found significantly associated in these independent
populations of patients. Last but not least, the GF100472
microsatellite polymorphism included in haplotypes HAP4 and
HAP5 and situated within the C3 promoter region, influenced
the promoter activity of C3 in vitro.
Indeed and as is always desirable in genetic association studies,
we showed here that the newly discovered GF100472 micro-
satellite (CA-repeat) polymorphism had functional consequences.
Generally, CA-repeats are purine-pyrimidine alternating se-
quences and hence have the potential to assume Z-DNA
conformation, a left-handed double-helix structure that is
thermodynamically unfavorable compared to B-DNA conforma-
tion. Z-DNA conformation has been described as negatively
affecting transcriptional activity[36,43]. Consistently, we showed
that GF100472 regulated C3 promoter activity in a length-
dependent manner: the longer the CA-repeat, the lower the
transcriptional activity. GF100472 may at least partly influence
genetic risks to epilepsy and epileptic seizures by modulating the
relative amounts of C3 transcripts. Interestingly, the IL-1b
cytokine that had shown genetic association with FS and with
MTLE[44] also influences C3 promoter activity through regula-
tory binding elements situated in the C3 promoter region[31,33].
The promoter activities associated with the GF100472 alleles did
not vary by more than 20%. Such a moderate effect is consistent
with the participation of such alleles as susceptibility factors in
multigenic disorder, as compared with the direct and more
dramatic effects of mutations in monogenic disorders.
C3 might be involved in genetic risks for human MTLE and for
FS at various and non-exclusive levels and time-points. As the
central component of the complement system, C3 influences
susceptibility to infectious and febrile episodes during infancy.
Hence C3 could indirectly modulate susceptibility to FS, whether
simple or complex. The complement system might also play a
role in the developing nervous system by tagging unwanted
synapses for elimination[2]. Inter-individual variations of C3
expression during brain development would then influence the
building of neuronal circuits and the labeling of imprecise
connections, hence favoring future susceptibility to seizures and
epilepsy. Later in life, MTLE pathogenesis might also involve the
reactivation of such developmental and complement-dependent
remodeling pathways, while the complement system and C3
particularly, may also trigger neuroprotective effects during the
latency period of MTLE. Overall C3-dependent susceptibility to
FS and to MTLE-FS+ might rely on a very precise albeit evolving
balance between beneficial and detrimental effects of the
complement system.
Materials and Methods
Ethic statement
All clinical investigations were conducted according to the
Declaration of Helsinki. Written informed consent was obtained
from all participating subjects. The Research Ethics Board of the
Department of Clinical Neurosciences of Geneva and the Medical
University of Vienna reviewed and approved the study.
Patients
Demographic and clinical characteristics of all MTLE, FS
patients and all matched controls are summarized in Table 1.
The first series of 122 mesial temporal lobe epilepsy (MTLE)
consisted in patients who were consecutively admitted in the
Epilepsy Unit of the University Hospital of Montpellier, France.
This series was designated as MT-1, while the second series (MT-2)
of 199 MTLE patients was recruited at the Department of
Neurology of the Medical University of Vienna, Austria (Table 1).
All patients had a severe form of epilepsy with poor control of their
seizures, although they were treated with two or three single anti-
epileptic drugs or a combination of drugs. Diagnosis was based on
patient history with a particular focus on possible history of febrile
seizures (FS), clinical examination, interictal and ictal EEG analysis
carried out with monitoring video-EEG, and MRI evaluation.
Patients with FS were admitted in the pediatric emergency
rooms from the University Hospitals of Geneva, Lausanne and
Neucha ˆtel (Switzerland) for the first series of 97 FS patients (series
FS-1), and at Department of Pediatrics, LKH Bregenz and
Department of Pediatrics, Medical University of Graz, Austria for
the replication series of 148 FS patients (series FS-2). Simple FS
were diagnosed when seizures were brief and lacked focal features,
with a single seizure during a febrile illness. Complex FS were
diagnosed if duration lasted more than 15 min, if focal features
were present, or if multiple seizures occurred during a single
febrile illness or within the first 24 h period.
Healthy control groups were recruited among blood donors
from the University Hospital of Geneva, Switzerland (first series of
196 healthy individuals (HI), thereafter designated as series HI-1;
third series of 301 controls, designated as series HI-3) and from
healthy individuals in Vienna, Austria (second series of 255
controls, designated as series HI-2). To minimize morbidity among
subjects in these control groups, only blood donors older than 35
years and without history of epilepsy and seizure were included.
Patients and controls were European Caucasians. Written informed
consent was obtained from all participating subjects (see above).
Genotyping
The C3 promoter region contains a novel dinucleotide (CA)
repeat polymorphism (Genbank GF100472). Oligonucleotides
flanking this marker were used as primers (Table S4). PCR reaction
was carried out with 100 ng of genomic DNA using Hot Star Taq
DNA polymerase (Qiagen, Hilden, Germany) in a 25 ml reaction
mix containing 16 buffer (Tris?Cl, KCl, (NH4)2SO4,15 mM
MgCl2; pH 8.7), 0.12 mM dNTPs, 0.08 mM deaza-dNTPs, 5%
DMSO, 0.4 mM primers, 1 U Taq polymerase. Amplification
conditions were as follows: 95uC for 15 minutes, 30 cycles of 92uC
for 1 minute, 52uC for 30 seconds and 72uC for 1 minute. For series
MT-1, FS-1, HI-1 and HI-3, PCR products were analyzed by
electrophoresis on a 10% polyacrylamide gel stained with ethidium
bromide. For Austrian samples (series MT-2, FS-2 and HI-2) PCRs
were performed with fluorescently labeled oligonucleotides and
PCR products were separated on an ABI3130 Genetic Analyzer.
Allele (CA)8 was 132 nucleotides (nt), allele (CA)9 was 134 nt, allele
(CA)10 was 136 nt, allele (CA)11 was 138 nt, allele (CA)12 was
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(CA)15 was 146 nt. Single nucleotide polymorphisms (rs339392,
rs2230199, rs428453, rs344550, and rs379527; dbSNP database at
http://www.ncbi.nlm.nih.gov/SNP/) were analyzed either by
direct sequencing (series MT-1, FS-1, HI-1) (ABI3700 DNA
Analyzer
TM, Applied Biosystems) or (series MT-2, FS-2 and HI-2)
by genotyping in 20 ml reaction volumes using commercially
available Taq Man-based allelic discrimination assays (7700
detection system, Applied Biosystems) and standard procedures
based on Applied Biosystems reagents. The list of all primers used
for the corresponding PCRs is given in Table S4.
Statistical analysis
Allele and genotype comparisons between controls and MTLE,
controls and MTLE with hippocampal sclerosis (MTLE-HS+),
controls and MTLE with history of FS (MTLE-FS+), and controls
and FS were made using maximum likelihood inference as
implanted in UNPHASED[45], which was moreover used because
it allows the use of multi-allelic markers. Haplotype analysis was
done following the same method where the null hypothesis is that
none of the test haplotypes makes any contribution. All rare
haplotypes with frequencies below 1% in both controls and
patients populations were excluded from analysis, since an
individual haplotype analysis would have limited statistical power.
We used a sliding window procedure to extract the core haplotype
associated with the trait, starting with six polymorphisms
haplotype analysis and reducing the window on selected and
significant haplotypes only.
Since we compared genotypic and allelic distributions of six
polymorphic markers between controls and three related sub-
groups (MTLE, MTLE-HS+ and MTLE-FS+) in the first MTLE
study (series MT-1 and HI-1), a correction for multiple testing was
required. Two approaches were applied to correct for multiple
non-independent comparisons. First, we used the highly con-
servative Bonferroni correction taking into account the non-
independence of tests. We effectively tested three independent
polymorphisms, since there was strong linkage disequilibrium (LD)
between some of the polymorphisms (Table S5). Indeed,
GF100472, rs339392 and rs2230199 were in strong LD with
each others, as were rs344550 and rs379527, whereas rs428453
appeared separated from the others. Two independent tests were
moreover considered for the different MTLE subgroups. As the
haplotype test was a post-hoc analysis, we considered it as one
additional test. Therefore, for a Bonferroni correction on the p-
values, we used p=0.05/(362+1) =0.0071 as a threshold for
significance. Three unrelated samples of independent MTLE-FS+
and FS patients collected in Geneva (FS-1) and in Vienna (MT-2,
FS-2), were used in the subsequent studies and the same threshold
of significance was applied for the corresponding tests. Second, we
applied the false discovery rate to quantify uncertainty across the
multiple hypotheses tested in the six single marker tests and the
multiple haplotype tests. The false discovery rate q value was
therefore calculated, which denotes the expected proportion of
false negatives among multiple findings. Based on the single
markers and haplotypes association results, the q-value for each of
these non-independent tests was calculated using the step-up
procedure[46]. The q-value calculated in this way has been shown
to retain desirable properties for multiple related tests in genetic
association studies and can be intuitively interpreted in terms of
posterior error probability.
Statistical power to detect associations was estimated using
the Genetic Power Calculator (http://pngu.mgh.harvard.edu/
purcell/gpc/). Thus, we determined that the case-MTLE
sample in the first MTLE study had 79% power to detect a
risk allele with 15% frequency and using an additive genotype
model at alpha of 0.0071. The power dropped to 68% for the
MTLE-HS+ and 56% for the MTLE-FS+. For the second
MTLE-FS+ population and for the FS populations collected in
Switzerland (FS-1) and in Austria (FS-2), powers were at 50%,
72% and 86%, respectively.
Gene reporter assays
For luciferase gene reporter experiments, several variants of the
promoter region of the C3 gene, from nucleotides (nt) 21021 to
+61 with respect to the canonical transcription start site (Figure 1),
were amplified by polymerase chain reaction (PCR) from genomic
DNAs of healthy donors. Primers used were as follows:
PROM_C3.F: 59– AAAAAGAGCTCGGGATGGGAGGAA-
GACCA; PROM_C3.R: 59– AAAAAAGATCTGGTGCTGG-
GACAGTGCA. Each promoter region with either of GF100472
alleles (CA)8, (CA)9, (CA)10, (CA)11 and (CA)15, was subcloned
into the pGL2 vector (Promega), 59 to the coding sequence of the
firefly luciferase reporter gene. Direct sequencing was used to
confirm the integrity of the constructions and to verify that the
variants only differed in the number of CA-repeats. HEK293T
cells were grown in 5% CO2 at 37uC in Dulbecco’s Modified
Eagles Medium (DMEM) (Lonza) supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and
10% Fetal Calf Serum. One day before transfection, cells were
seeded in six-well plates with a concentration of 105 cells/well.
When cells reached 70–80% confluence, they were transiently
cotransfected using the Lipofectamine Plus
TM reagent (Invitrogen)
according to the manufacturer’s instructions, with 1 mg of either
appropriate reporter construct (pGL2-basic for negative control,
pGL2-C3 variant constructs for the analysis of each corresponding
promoter activity) and with 150 ng of pHSV-LacZ vector for
normalization. Forty-eight hours after transfection, cells were lysed
with 150 ml of Reporter Lysis Buffer (Promega). Firefly luciferase
activity was quantified using the Luciferase Assay System
(Promega) on a LB9507 Luminometer (Lumat). LacZ activity
was measured using the b-Galactosidase Enzyme Assay System
(Promega) on a NanoDrop
TM 1000 (Thermo Fisher Scientific). All
transfections were performed in triplicate and repeated in three
independent experiments (nine biological replicates in total) for all
the variants that were subcloned. The relative luciferase activities
were then calculated with correction for transfection by b-
Galactosidase activity. Another set of nine replicates was also
performed with the constructs corresponding to the most extreme
allele sizes, i.e. (CA)8 and (CA)15. Data were expressed as mean 6
SEM. Statistical significance was assessed using unpaired t tests
(two-tailed).
Supporting Information
Table S1 Allele and genotype frequencies in the control and
patients populations for polymorphism markers used in this study.
Found at: doi:10.1371/journal.pone.0012740.s001 (0.07 MB
DOC)
Table S2 Single locus analysis of the C3 gene.
Found at: doi:10.1371/journal.pone.0012740.s002 (0.11 MB
DOC)
Table S3 Three-locus haplotype analysis of the C3 gene in
MTLE patients and in pure FS patients.
Found at: doi:10.1371/journal.pone.0012740.s003 (0.08 MB
DOC)
Table S4 List of PCR primers.
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Table S5 Linkage disequilibrium (LD) data.
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DOC)
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